video corpo

LT033 RIQAS Explained
1 / 64ページ

{{requestButtons}}

カタログの抜粋

LT033 RIQAS Explained - 1

RANDOX INTERNATIONAL QUALITY ASSESSMENT SCHEME

カタログの1ページ目を開く
LT033 RIQAS Explained - 2

RIQAS THE LARGEST INTERNATIONAL EQA SCHEME WITH OVER 55,000 LAB PARTICIPANTS

カタログの2ページ目を開く
LT033 RIQAS Explained - 3

RIQAS REPORTS WEB-BASED DATA TRANSFER STANDARD REPORT END-OF-CYCLE REPORT MULTI-INSTRUMENT REPORT URINE TOXICOLOGY REPORT URINALYSIS REPORT SEROLOGY REPORT SERUM INDICES REPORT BACTERIAL IDENTIFICATION REPORT RIQAS PROGRAMMES PARAMETER INDEX

カタログの3ページ目を開く
LT033 RIQAS Explained - 4

BENEFITS Delivering a comprehensive yet cost effective EQA solution, RIQAS will help meet regulatory requirements and increase confidence in test system accuracy. Large Database of Users • A high level of participation means peer group numbers are maximised whilst ensuring availability of data for a wide range of instruments and methods. User-friendly Reports • Simple, one page per parameter format, enables at-a-glance performance assessment, saving valuable laboratory time. • Complimentary multi-instrument and interlaboratory reports allow comparative performance assessment of all...

カタログの4ページ目を開く
LT033 RIQAS Explained - 5

RIQAS Programmes • Ammonia/Ethanol • Anti-Mullerian Hormone (AMH) • Anti-TSH Receptor • Blood Gas • BNP • Cardiac • Cardiac Plus • Cerebrospinal Fluid (CSF) • Clinical Chemistry • Coagulation • CO-Oximetry • CYFRA 21-1 • Cytokines ESR Glycated Haemoglobin (HbA1c) • Haematology • Human Urine • Immunoassay • Immunoassay Speciality 1 • Immunoassay Speciality 2 • Immunosuppressant Drugs • Lipids • Maternal Screening Microbiology (Bacterial Identification) • Neonatal Bilirubin • Serology (Anti-SARS-CoV-2) • Serology Epstein Barr Virus (EBV) • Serology (HIV/Hepatitis) • Serology (Syphilis) •...

カタログの5ページ目を開く
LT033 RIQAS Explained - 6

RIQAS REPORTS RIQAS reports are presented in a user-friendly, one page per parameter format. This allows easy interpretation of your analytical performance. RIQAS Reports • tatistical breakdown by all methods, your method S and, where applicable, your instrument, including running means for the last 10 samples. • ompare your instrument group, method group C and all methods using the histogram. • Identify trends, biases and precision problems using the visual charts. • The Target Score chart uniquely grades your performance in a moving window over the last 20 samples, including the previous...

カタログの6ページ目を開く
LT033 RIQAS Explained - 7

WEB-BASED DATA TRANSFER RIQAS.Net offers easy, direct access for the submission of results and retrieval of reports direct from the RIQAS host server. • Available in multiple languages. • Confidentiality and security is maintained through the use of password protected access. • Submit current, corrected and future results (normal policies apply), directly into the RIQAS database. Receipt of results is confirmed by e-mail. •Multi-lingual registration identifier provides simple identification of multiple registrations. • Additions and changes to assay details can be made quickly and easily...

カタログの7ページ目を開く
LT033 RIQAS Explained - 8

PARTICIPATION IN RIQAS Participation in RIQAS follows these simple steps: Order your RIQAS programmes through your local Randox Office or Distributor. Register the instruments and methods used in your lab on RIQAS.net or by completing the enrolment document. Enrolment documents are available from riqas.com and should be submitted 3 weeks before the cycle starts. Check RIQAS policies in method questionnaire. Analyse the sample on the recommended date, carefully following the instructions for use. Enter your results via RIQAS.Net and submit before the final deadline. Receive a set of numbered...

カタログの8ページ目を開く
LT033 RIQAS Explained - 9

STANDARD REPORT Performance data is presented in a one page format with up to seven sub-reports. )NWEQUG OIFN #EEGRVCDNG NKOKVU FGTKXGF HTQO $KQNQIKECN 8CTKCVKQP #EEGRVCDNG NKOKVU QH RGTHQTOCPEG HQT 4+3#5 *GZQMKPCUG )NWEQUG QZKFCUG 1TVJQ 8KVTQU /KETQ5NKFG 5[UVGOU )NWEQUG FGJ[FTQIGPCUG )1&$GEMOCP OGVJQF 1VJGT &T[ %JGOKUVT[ #ICRRG )1&2#2 1Z[IGP GNGEVTQFG 8KVTQU &6&6 ++ Text Section Chart: Statistics for all methods, your method and instrument group (programme specific). Histogram Chart: Method and instrument comparison. Multi-Method Stat Section Chart: Enables assessment of the performance of...

カタログの9ページ目を開く
LT033 RIQAS Explained - 10

TEXT SECTION The text section summarises the statistical information for each parameter. /106*.; %.+0+%#. %*'/+564; )NWEQUG OIFN RIQAS performance indicators include SDI, Target Score and %Deviation. Acceptable performance criteria: 6&2# SDI < 2 Target score 50 %Deviation ≤ defined acceptable limits #EEGRVCDNG NKOKVU QH RGTHQTOCPEG HQT 4+3#5 #EEGRVCDNG NKOKVU FGTKXGF HTQO $KQNQIKECN 8CTKCVKQP Performance statement appears here if performance indicators exceed limits Number of returned results used to generate Mean for Comparison. After statistical reduction, some results are excluded from...

カタログの10ページ目を開く
LT033 RIQAS Explained - 11

/GCP/GCP HQT %QORCTKUQP HQT %QORCTKUQP The Bar Graph is intended as a quick visualisation of how your lab’s result compares to the method mean, instrument mean and all method mean. Your instrument group (programme specific) Your method group #EEGRVCDNG NKOKVU NKOKVU QH RGTHQTOCPEG4+3#5 #EEGRVCDNG QH RGTHQTOCPEG HQT HQT 4+3#5 #EEGRVCDNG NKOKVU NKOKVU FGTKXGF $KQNQIKECN 8CTKCVKQP #EEGRVCDNG FGTKXGF HTQO HTQO $KQNQIKECN 8CTKCVKQP *GZQMKPCUG *GZQMKPCUG )NWEQUG QZKFCUG )NWEQUG QZKFCUG 1TVJQ 1TVJQ 8KVTQU /KETQ5NKFG 5[UVGOU 8KVTQU /KETQ5NKFG 5[UVGOU )NWEQUG FGJ[FTQIGPCUG )NWEQUG FGJ[FTQIGPCUG...

カタログの11ページ目を開く
LT033 RIQAS Explained - 12

This section provides an easy way of assessing the performance of other methods used to analyse the parameter in question. Hexokinase Glucose oxidase Ortho Vitros MicroSlide Systems Glucose dehydrogenase GOD/02-Beckman method Other Dry Chemistry Agappe - GOD-PAP Oxygen electrode Vitros, DT60/DT60 II

カタログの12ページ目を開く
LT033 RIQAS Explained - 13

LEVEY-JENNINGS CHART SDIs reflect laboratory performance in relation to fit-for-purpose SDPAs and are useful to monitor performance over time. Acceptable performance is SDI < 2. N = No result returned in time for this registration\sample. C = Corrected results will be accepted for non-analytical errors. Corrected results will be accepted up to 4 weeks after the final submission deadline, on application, with evidence of analysis. Late results are only accepted if there has been a Randox error. This line indicates change in registration details for this a parameter. Sample number. The Mean...

カタログの13ページ目を開く

Randox Laboratories/ランドックスのすべてのカタログと技術パンフレット

  1. Acusera 24.7

    24 ページ

  2. Company Overview

    40 ページ

  3. Reagents Brochure

    64 ページ

  4. sdLDL-C

    8 ページ

  5. RX modena

    20 ページ

  6. RX misano

    20 ページ

  7. RX Daytona Plus

    20 ページ

  8. Rx Imola

    20 ページ

  9. RX Monaco

    20 ページ

  10. 2024 Product List

    64 ページ

  11. VeraSTAT-V

    16 ページ

  12. VERASTAT

    16 ページ

  13. Endocrine Array

    4 ページ

  14. Cerebral Arrays

    4 ページ

  15. Thyroid Arrays

    4 ページ

  16. Basic QC Stastics

    8 ページ

  17. Qnostics

    52 ページ

  18. Adiponectin LT519

    28 ページ

  19. Specific Proteins

    40 ページ

  20. Linearity sets

    12 ページ

  21. Antioxidants

    16 ページ

  22. Diabetes Portfolio

    28 ページ

  23. Total Bile Acids

    4 ページ

  24. VIVALYTIC

    30 ページ

  25. RANDOX DISCOVERY

    36 ページ

  26. HbA1c

    2 ページ

  27. Preparing QC

    1 ページ

カタログアーカイブ

  1. ACUSERA

    108 ページ

  2. Evidence Evolution

    28 ページ

  3. Evidence

    16 ページ

  4. Molecular Testing

    16 ページ

  5. Fertility Array

    4 ページ

  6. Rx Daytona

    16 ページ

  7. Evidence

    16 ページ